Context Therapeutics (NASDAQ:CNTX) and Nature’s Sunshine Products (NASDAQ:NATR) Critical Analysis

Nature’s Sunshine Products (NASDAQ:NATR) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Analyst Ratings

This is a summary of current ratings for Nature’s Sunshine Products and Context Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nature’s Sunshine Products	0	0	3	0	3.00
Context Therapeutics	1	0	6	1	2.88

Nature’s Sunshine Products currently has a consensus price target of $35.00, indicating a potential upside of 60.18%. Context Therapeutics has a consensus price target of $6.60, indicating a potential upside of 153.85%. Given Context Therapeutics’ higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Nature’s Sunshine Products.

Profitability

This table compares Nature’s Sunshine Products and Context Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nature’s Sunshine Products	4.06%	14.67%	9.27%
Context Therapeutics	N/A	-59.95%	-54.78%

Volatility and Risk

Nature’s Sunshine Products has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Institutional & Insider Ownership

79.4% of Nature’s Sunshine Products shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 3.1% of Nature’s Sunshine Products shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Nature’s Sunshine Products and Context Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nature’s Sunshine Products	$480.14 million	0.80	$19.52 million	$1.10	19.86
Context Therapeutics	N/A	N/A	-$36.12 million	($0.42)	-6.19

Nature’s Sunshine Products has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Nature’s Sunshine Products, indicating that it is currently the more affordable of the two stocks.

Summary

Nature’s Sunshine Products beats Context Therapeutics on 9 of the 14 factors compared between the two stocks.

About Nature’s Sunshine Products

Nature’s Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature’s Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature’s Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.

About Context Therapeutics

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.